NCT01855100View on ClinicalTrials.gov

Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)

CompletedOBSERVATIONAL
Enrollment

131

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

December 31, 2014

Conditions
Venous Thrombosis
Interventions
DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Bayer

INDUSTRY